2 results
Approved WMOCompleted
Primary: To determine whether treatment with BKM120 plus fulvestrant prolongs PFS based on local investigator assessment compared to treatment with placebo plus fulvestrant for all patients regardless of PI3K pathway activation status (unkown status…
Approved WMORecruiting
To investigate whether enhanced expression of growth factor receptors (FGF-R, PDGF-R and VEGF-R) and increasedvascular cell proliferation in the lung of IPF or PAH patients can be assessed using [11C]-Nintedanib or [18F]-FLTPET/CT imaging.